Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia

1 Jan 2023

Abstract excerpt

: termination of DNA replication at high doses, and inhibition of DNA methyltransferase at low doses. The alteration of DNA methylation patterns by low-dose decitabine is hypothesized to upregulate genes, which promote myeloblast differentiation. In a phase III clinical trial, low-dose decitabine achieved a superior overall response rate (ORR) when compared with 'treatment choice' [consisting of low-dose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37854355
DOI: 10.1177/20406207231205429

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemiaPMID 37854355Read ↗

Decitabine and its role in the treatment of hematopoietic malignanciesSemantic proximity Read ↗

DecitabineSemantic proximity Read ↗

Evolution of decitabine developmentSemantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid LeukemiaSemantic proximity Read ↗

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AMLSemantic proximity Read ↗

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemiaSemantic proximity Read ↗

Decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 studySemantic proximity Read ↗

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemiaSemantic proximity Read ↗

Recurrent transcriptional responses in AML and MDS patients treated with decitabineSemantic proximity Read ↗

DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.